In a Phase 1 randomized, double-blind, placebo-controlled trial involving obese adults (NCT04478708), AMG 133 exhibited good safety and tolerability profiles and demonstrated significant dose-dependent weight loss effects
Protein consumption triggers release of multiple satiety hormones including GLP-1, peptide YY (PYY), and cholecystokinin (CCK)
Other studies have found that the level of GPX4 in brain tissue decreases significantly 24 h after cerebral hemorrhage, while increasing the level of GPX4 significantly reduces neuronal dysfunction, brain edema, blood-brain barrier damage, oxidative stress and inflammatory damage after cerebral hemorrhage, and the application of the ferroptosis inhibitor Fer-1 also significantly reduces the extent of secondary brain injury after cerebral hemorrhage 74
Book a consultation today to see whether GLP-1 therapy fits your weight management goals
Access is limited to authorized researchers and requires approval from the institutional review board (IRB) at Jikei University Hospital
